Equities research analysts expect that Kindred Biosciences, Inc. (NASDAQ:KIN) will report earnings per share of ($0.33) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Kindred Biosciences’ earnings. Kindred Biosciences posted earnings per share of ($0.29) during the same quarter last year, which indicates a negative year-over-year growth rate of 13.8%. The business is scheduled to issue its next quarterly earnings report after the market closes on Tuesday, November 7th.

On average, analysts expect that Kindred Biosciences will report full-year earnings of ($1.18) per share for the current fiscal year. For the next financial year, analysts anticipate that the firm will post earnings of ($0.98) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Kindred Biosciences.

Kindred Biosciences (NASDAQ:KIN) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04.

Separately, Zacks Investment Research raised shares of Kindred Biosciences from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a report on Wednesday, September 6th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $9.19.

WARNING: “Kindred Biosciences, Inc. (KIN) Expected to Announce Earnings of -$0.33 Per Share” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/04/kindred-biosciences-inc-kin-expected-to-announce-earnings-of-0-33-per-share.html.

Institutional investors have recently added to or reduced their stakes in the business. Nationwide Fund Advisors bought a new position in Kindred Biosciences in the 2nd quarter valued at about $100,000. JPMorgan Chase & Co. bought a new position in Kindred Biosciences in the 2nd quarter valued at about $119,000. Trexquant Investment LP bought a new position in Kindred Biosciences in the 2nd quarter valued at about $120,000. OxFORD Asset Management LLP bought a new position in Kindred Biosciences in the 2nd quarter valued at about $128,000. Finally, State of Wisconsin Investment Board bought a new position in Kindred Biosciences in the 2nd quarter valued at about $129,000. 60.37% of the stock is currently owned by hedge funds and other institutional investors.

Kindred Biosciences (KIN) traded down $0.05 during trading on Friday, hitting $7.25. The stock had a trading volume of 56,452 shares, compared to its average volume of 86,553. Kindred Biosciences has a twelve month low of $3.90 and a twelve month high of $9.65.

About Kindred Biosciences

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.